Selection of Natural Compounds with HMGA-Interfering Activities and Cancer Cell Cytotoxicity.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
12 Sep 2023
12 Sep 2023
Historique:
received:
27
03
2023
accepted:
30
06
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
HMGA proteins are intrinsically disordered (ID) chromatin architectural factors characterized by three DNA binding domains (AT-hooks) that allow them to bind into the DNA minor groove of AT-rich stretches. HMGA are functionally involved in regulating transcription, RNA processing, DNA repair, and chromatin remodeling and dynamics. These proteins are highly expressed and play essential functions during embryonic development. They are almost undetectable in adult tissues but are re-expressed at high levels in all cancers where they are involved in neoplastic transformation and cancer progression. We focused on identifying new small molecules capable of binding into the minor groove of AT-rich DNA sequences that could compete with HMGA for DNA binding and, thus, potentially interfere with their activities. Here, a docking-based virtual screening of a unique high diversity in-house library composed of around 1000 individual natural products identified 16 natural compounds as potential minor groove binders that could inhibit the interaction between HMGA and DNA. To verify the ability of these selected compounds to compete with HMGA proteins, we screened them using electrophoretic mobility shift assays. We identified Sorocein C, a Diels-Alder (D-A)-type adducts, isolated from
Identifiants
pubmed: 37720761
doi: 10.1021/acsomega.3c02043
pmc: PMC10500574
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32424-32431Informations de copyright
© 2023 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Gen Pharmacol. 1993 Jul;24(4):983-9
pubmed: 7901116
Nucleic Acids Res. 2016 Dec 15;44(22):e162
pubmed: 27587582
Eur J Med Chem. 2018 Jan 20;144:277-288
pubmed: 29275228
Recent Pat Anticancer Drug Discov. 2019;14(3):258-267
pubmed: 31538905
Angew Chem Int Ed Engl. 2008;47(17):3258-61
pubmed: 18348121
Sci Rep. 2017 May 19;7(1):2213
pubmed: 28526832
Int J Mol Sci. 2020 Jan 22;21(3):
pubmed: 31979076
Nat Rev Cancer. 2007 Dec;7(12):899-910
pubmed: 18004397
PLoS One. 2012;7(5):e37120
pubmed: 22615915
Virus Res. 2017 Jun 15;238:236-242
pubmed: 28684158
Biochem Pharmacol. 1988 Dec 15;37(24):4727-33
pubmed: 2462423
Br J Cancer. 2014 Aug 12;111(4):646-50
pubmed: 24755886
Proteomics. 2005 Apr;5(6):1494-506
pubmed: 15798993
Biochem J. 2009 Feb 15;418(1):103-12
pubmed: 18937643
ACS Med Chem Lett. 2019 Feb 26;10(4):639-643
pubmed: 30996810
Cancer Cell Int. 2020 May 24;20:192
pubmed: 32489328
Int J Biol Sci. 2022 Jul 4;18(11):4414-4431
pubmed: 35864955
Eur J Cancer. 2013 Mar;49(5):1142-51
pubmed: 23149213
Cancer Res. 2018 Apr 15;78(8):1890-1897
pubmed: 29618461
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
J Mol Med (Berl). 2017 Apr;95(4):353-360
pubmed: 28293697
J Nat Prod. 2016 Oct 28;79(10):2495-2503
pubmed: 27656763
Pharmaceutics. 2021 Oct 03;13(10):
pubmed: 34683905
Anal Biochem. 2008 Mar 1;374(1):7-15
pubmed: 18023407
Gene. 2001 Oct 17;277(1-2):63-81
pubmed: 11602345
Expert Opin Ther Targets. 2014 May;18(5):541-53
pubmed: 24684280
J Chem Inf Model. 2005 May-Jun;45(3):542-8
pubmed: 15921444
PLoS One. 2013 May 02;8(5):e63419
pubmed: 23658826
FASEB J. 2001 Feb;15(2):492-500
pubmed: 11156965
Acta Neuropathol. 2012 Apr;123(4):553-71
pubmed: 22249617
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):216-229
pubmed: 29518471
Biochem Biophys Res Commun. 1990 Feb 14;166(3):1110-7
pubmed: 2154972
EMBO J. 1999 Jun 1;18(11):3074-89
pubmed: 10357819
Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):37-47
pubmed: 19732855
Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):3-14
pubmed: 19748605
Cancer Res. 1988 Feb 1;48(3):589-601
pubmed: 3335022
J Org Chem. 2020 Aug 21;85(16):10891-10901
pubmed: 32806095
Biochim Biophys Acta. 2008 Sep;1784(9):1159-66
pubmed: 18513496
Science. 2001 Aug 10;293(5532):1133-6
pubmed: 11498590
Oncotarget. 2013 Aug;4(8):1293-308
pubmed: 23945276
Biochemistry. 2003 Apr 22;42(15):4569-77
pubmed: 12693954
PLoS One. 2010 May 14;5(5):e10656
pubmed: 20498830
Technol Cancer Res Treat. 2002 Oct;1(5):393-9
pubmed: 12625765
Expert Opin Ther Targets. 2020 Oct;24(10):953-969
pubmed: 32970506
EMBO J. 2015 Jan 13;34(2):200-17
pubmed: 25476449
FEBS Lett. 2004 Sep 10;574(1-3):1-8
pubmed: 15358530
Br J Haematol. 2015 Dec;171(5):818-29
pubmed: 26403224
Proteomics. 2008 Nov;8(22):4721-32
pubmed: 18850631